RGC

+ Watchlist + Portfolio

Regencell Bioscience Holdings Limited

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.81
52-Week Range: $4.51 – $69.00
Market Cap: —
P/E (TTM): —
EPS (TTM): -0.01
Dividend Yield: —

Advanced Metrics

Price/Book: 2720.00
PEG Ratio: —
Return on Equity: -177.66%
Return on Assets: -84.97%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.42
Debt/Equity: 0.32
Total Debt: $386.30K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.87B

RGC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	—
Research & Development	$2.51M	$1.58M	$1.07M	—
Selling, General & Admin	$5.11M	$4.69M	$3.67M	—
Operating Expenses	$7.62M	$6.27M	$4.74M	—
Operating Income	-$7.62M	-$6.27M	-$4.74M	—
EBITDA	-$7.01M	-$5.50M	-$3.99M	—
Pretax Income	-$7.59M	-$6.06M	-$4.36M	—
Income Tax	$0.00	$0.00	$0.00	—
Net Income	-$7.45M	-$5.87M	-$4.30M	—
Diluted EPS	-0.02	-0.01	-0.01	-0.01
Diluted Shares	486.62M	494.49M	494.49M	494.49M

Market Snapshot

About

Regencell Bioscience Holdings is a biotech company developing traditional Chinese medicine-based therapies for neurocognitive disorders. The company focuses on treating attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) through proprietary herbal formulations. Regencell conducts clinical research to validate the efficacy of traditional remedies using modern scientific methods.

USD	Q4 2024	Q4 2025
Current Assets	$6.59M	$2.36M
Total Assets	$7.48M	$3.01M
Total Liabilities	$763.84K	$1.79M
Shareholders' Equity	$6.72M	$1.22M